Phase 1
Completed N=25
Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane
Degradation of Top2b and Top2a in Human by Dexrazoxane · Time Course and Degradation of Top2b in Human by Dexrazoxane · Effects of Dexrazoxane on Healthy Human
Source: ClinicalTrials.gov NCT03930680 ↗
Enrolled (actual)
25
Serious AEs
0.0%
Results posted
Jun 2025
Primary outcomePrimary: Participants With 95% Reduction in Topoisomerase 2 b From Baseline — 0; 0; 0; 0 Participants
Summary
The purpose of this research study is to determine whether early administration of Dexrazoxane prevents Doxorubicin induced cardiotoxicity.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Participants With 95% Reduction in Topoisomerase 2 b From Baseline |
0; 0; 0; 0; 1 | — |
Eligibility Criteria
Inclusion Criteria
- Women,
- Age 18-65,
- Not pregnant, Not currently breast feeding
- No current illness,
Exclusion Criteria
- Pregnancy, currently breast feeding
- Current illness,
- History of cardiac, or renal disease
Data sourced from ClinicalTrials.gov (NCT03930680). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.